Clearpoint Neuro Stock Analysis

CLPT Stock  USD 11.09  0.13  1.19%   
Clearpoint Neuro is overvalued with Real Value of 9.74 and Target Price of 14.5. The main objective of Clearpoint Neuro stock analysis is to determine its intrinsic value, which is an estimate of what Clearpoint Neuro is worth, separate from its market price. There are two main types of Clearpoint Neuro's stock analysis: fundamental analysis and technical analysis.
The Clearpoint Neuro stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Clearpoint Neuro is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Clearpoint Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Clearpoint Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy Clearpoint Stock please use our How to Invest in Clearpoint Neuro guide.

Clearpoint Stock Analysis Notes

About 31.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.69. Clearpoint Neuro last dividend was issued on the 27th of July 2016. The entity had 1:40 split on the 27th of July 2016. ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California. Clearpoint Neuro operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 80 people. For more info on Clearpoint Neuro please contact Joseph Burnett at 888 287 9109 or go to https://www.clearpointneuro.com.

Clearpoint Neuro Quarterly Total Revenue

8.12 Million

Clearpoint Neuro Investment Alerts

Clearpoint Neuro generated a negative expected return over the last 90 days
Clearpoint Neuro has high historical volatility and very poor performance
The company reported the previous year's revenue of 23.95 M. Net Loss for the year was (22.09 M) with profit before overhead, payroll, taxes, and interest of 13.53 M.
Clearpoint Neuro currently holds about 45.14 M in cash with (13.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.84.
Latest headline from gurufocus.com: ClearPoint Neuro Inc Trading 6.12 percent Higher on Nov 14

Clearpoint Neuro Upcoming and Recent Events

6th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Clearpoint Largest EPS Surprises

Earnings surprises can significantly impact Clearpoint Neuro's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-03-01
2022-12-31-0.2-0.180.0210 
2021-11-09
2021-09-30-0.16-0.18-0.0212 
2024-05-07
2024-03-31-0.19-0.160.0315 
View All Earnings Estimates

Clearpoint Neuro Environmental, Social, and Governance (ESG) Scores

Clearpoint Neuro's ESG score is a quantitative measure that evaluates Clearpoint Neuro's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Clearpoint Neuro's operations that may have significant financial implications and affect Clearpoint Neuro's stock price as well as guide investors towards more socially responsible investments.

Clearpoint Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Legato Capital Management Llc2024-09-30
159 K
Lane Generational Llc2024-09-30
157.7 K
Jane Street Group Llc2024-06-30
144.1 K
Parsons Capital Management Inc2024-09-30
139 K
State Street Corp2024-06-30
129.5 K
Goldman Sachs Group Inc2024-06-30
126.6 K
Squarepoint Ops Llc2024-06-30
101.8 K
Y-intercept (hong Kong) Ltd2024-06-30
79.7 K
D. E. Shaw & Co Lp2024-06-30
79 K
Vanguard Group Inc2024-09-30
1.2 M
Millennium Management Llc2024-06-30
465.5 K
Note, although Clearpoint Neuro's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Clearpoint Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 305.91 M.

Clearpoint Profitablity

The company has Profit Margin (PM) of (0.6) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.64.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.53)(0.56)
Return On Capital Employed(0.64)(0.67)
Return On Assets(0.52)(0.54)
Return On Equity(1.04)(0.99)

Management Efficiency

Clearpoint Neuro has return on total asset (ROA) of (0.2804) % which means that it has lost $0.2804 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6836) %, meaning that it created substantial loss on money invested by shareholders. Clearpoint Neuro's management efficiency ratios could be used to measure how well Clearpoint Neuro manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.56 in 2024. Return On Capital Employed is likely to drop to -0.67 in 2024. At this time, Clearpoint Neuro's Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 1.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 4.7 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 0.86  0.90 
Tangible Book Value Per Share 0.82  0.86 
Enterprise Value Over EBITDA(7.52)(7.90)
Price Book Value Ratio 7.89  8.29 
Enterprise Value Multiple(7.52)(7.90)
Price Fair Value 7.89  8.29 
Enterprise Value157.9 M165.8 M
Effective leadership at Clearpoint Neuro drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Operating Margin
(0.64)
Profit Margin
(0.60)
Beta
1.108
Return On Assets
(0.28)
Return On Equity
(0.68)

Technical Drivers

As of the 22nd of November, Clearpoint Neuro shows the mean deviation of 2.79, and Risk Adjusted Performance of 5.0E-4. Clearpoint Neuro technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Clearpoint Neuro Price Movement Analysis

Execute Study
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Clearpoint Neuro middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Clearpoint Neuro. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Clearpoint Neuro Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Clearpoint Neuro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Clearpoint Neuro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Clearpoint Neuro insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
D'alessandro Danilo over a month ago
Disposition of 4824 shares by Dalessandro Danilo of Clearpoint Neuro at 5.74 subject to Rule 16b-3
 
Mazin Sabra over a month ago
Disposition of 7465 shares by Mazin Sabra of Clearpoint Neuro at 11. subject to Rule 16b-3
 
Fletcher R John over a month ago
Acquisition by Fletcher R John of 515 shares of Clearpoint Neuro at 11.21 subject to Rule 16b-3
 
Mazin Sabra over a month ago
Disposition of 6913 shares by Mazin Sabra of Clearpoint Neuro subject to Rule 16b-3
 
Joseph Burnett over two months ago
Acquisition by Joseph Burnett of 23704 shares of Clearpoint Neuro subject to Rule 16b-3
 
Joseph Burnett over two months ago
Disposition of 3236 shares by Joseph Burnett of Clearpoint Neuro at 11.26 subject to Rule 16b-3
 
Mazin Sabra over two months ago
Acquisition by Mazin Sabra of 6913 shares of Clearpoint Neuro subject to Rule 16b-3
 
D'alessandro Danilo over three months ago
Disposition of 1191 shares by Dalessandro Danilo of Clearpoint Neuro at 11.26 subject to Rule 16b-3
 
Joseph Burnett over three months ago
Disposition of 3236 shares by Joseph Burnett of Clearpoint Neuro at 11.26 subject to Rule 16b-3
 
Mazin Sabra over three months ago
Acquisition by Mazin Sabra of 767 shares of Clearpoint Neuro at 4.58 subject to Rule 16b-3
 
Richards Timothy T. over three months ago
Acquisition by Richards Timothy T. of 2069 shares of Clearpoint Neuro at 5. subject to Rule 16b-3
 
D'alessandro Danilo over three months ago
Acquisition by Dalessandro Danilo of 1913 shares of Clearpoint Neuro at 4.58 subject to Rule 16b-3

Clearpoint Neuro Outstanding Bonds

Clearpoint Neuro issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Clearpoint Neuro uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Clearpoint bonds can be classified according to their maturity, which is the date when Clearpoint Neuro has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Clearpoint Neuro Predictive Daily Indicators

Clearpoint Neuro intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Clearpoint Neuro stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Clearpoint Neuro Corporate Filings

13A
12th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
8th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
8K
7th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
4th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
F4
11th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F4
2nd of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F3
27th of August 2024
An amendment to the original Schedule 13D filing
ViewVerify
8K
26th of August 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Clearpoint Neuro Forecast Models

Clearpoint Neuro's time-series forecasting models are one of many Clearpoint Neuro's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Clearpoint Neuro's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Clearpoint Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Clearpoint Neuro prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Clearpoint shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Clearpoint Neuro. By using and applying Clearpoint Stock analysis, traders can create a robust methodology for identifying Clearpoint entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.92)(0.97)
Operating Profit Margin(0.94)(0.98)
Net Loss(0.92)(0.97)
Gross Profit Margin 0.57  0.75 

Current Clearpoint Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Clearpoint analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Clearpoint analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
14.5Strong Buy3Odds
Clearpoint Neuro current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Clearpoint analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Clearpoint stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Clearpoint Neuro, talking to its executives and customers, or listening to Clearpoint conference calls.
Clearpoint Analyst Advice Details

Clearpoint Stock Analysis Indicators

Clearpoint Neuro stock analysis indicators help investors evaluate how Clearpoint Neuro stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Clearpoint Neuro shares will generate the highest return on investment. By understating and applying Clearpoint Neuro stock analysis, traders can identify Clearpoint Neuro position entry and exit signals to maximize returns.
Begin Period Cash Flow27.6 M
Long Term Debt9.9 M
Common Stock Shares Outstanding24.6 M
Total Stockholder Equity21.2 M
Property Plant And Equipment NetM
Cash And Short Term Investments23.1 M
Cash23.1 M
Accounts Payable393 K
Net Debt-9.2 M
50 Day M A11.9424
Total Current Liabilities7.4 M
Other Operating Expenses46.4 M
Non Current Assets Total6.5 M
Non Currrent Assets Other495 K
Stock Based Compensation6.1 M

Additional Tools for Clearpoint Stock Analysis

When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.